

Beacon Pharmaceuticals PLC.

9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223.

Price Sensitive Information

We are pleased to inform you that, the Board of Directors of the Company in its 255th meeting held on today, October 15, 2026 at 3:30 p.m. has decided, declared and recommended in regard to 25th Annual General Meeting of the shareholders of the Company for the year ended June 30, 2026 as follows:

- **Date and time of 25th AGM** - **December 13, 2026, Sunday at 11:00 a.m.**
- **Venue** - **Digital platform subject to approval from BSEC**
- **Record date** - **November 10, 2026**
- **Recommended dividend** - **11% in cash (i.e. 1.10 taka per ordinary share of Tk. 10 each)**

Comparative Statement:

Particulars	2025-26 (Tk.)	2024-25 (Tk.)
Net Asset Value (NAV)	8,276,336,644	6,667,081,042
Net Asset Value (NAV) per share	35.83	28.86
Earnings Per Share (EPS)	8.41	4.10
Net Operating Cash Flow per share (NOCFPS)	9.68	6.93

EPS, NAV & NOCFPS: For the year ended 30 June 2026, the audited financial statements of Beacon Pharmaceuticals PLC show earnings per share (EPS) more than doubling to BDT 8.41 from BDT 4.10 (+105.19%), driven mainly by 30.96% higher sales. Net asset value (NAV) per share rose 24.14% to BDT 35.83 from BDT 28.86, as retained earnings strengthened shareholders' equity. Net operating cash flow per share (NOCFPS) increased 39.76% to BDT 9.68 from BDT 6.93, on higher receipts from customers and others.

New investment in oncology production facility 2: BPPLC hereby informs its shareholders and stakeholders that the Company will make an investment of BDT 250 crore in oncology production facility 2. Upon completion, annual production capacity will increase by 37.97 crore tablets, 21.10 crore capsules, 2.53 crore blisters and 2 crore vials injectable. The investment is expected to have a positive impact on the Company's revenue.

The Company will strengthen its R&D capabilities to enhance the regulatory readiness of its own drugs for SRA markets. Through rigorous research, product optimization and compliance with international quality standards, the Company will prepare its products for stringent regulatory assessment and approval.

By order of the Board

October 15, 2026

Sd/-
Anindya Sarkar FCS
Company Secretary

Note: The shareholders are also being requested for updating their respective BO account with 12 digits e-TIN number, BO account, address, mobile number, e-mail address etc. through their respective DPs before the Record Date i.e. November 10, 2026.